Capricor Therapeutics (NASDAQ:CAPR) Trading Down 4.7% – Here’s What Happened

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price fell 4.7% during trading on Thursday . The company traded as low as $12.91 and last traded at $12.56. 519,153 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 1,387,494 shares. The stock had previously closed at $13.18.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Performance

The firm has a market cap of $567.47 million, a PE ratio of -11.61 and a beta of 4.10. The stock’s fifty day moving average price is $14.08 and its 200-day moving average price is $14.82.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Sell-side analysts forecast that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Summit Investment Advisors Inc. increased its position in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth about $68,000. AlphaQuest LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $78,000. Finally, New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 5,000 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.